Download PDF
Dtsch Med Wochenschr 2020; 145(21): 1562-1568
DOI: 10.1055/a-1200-7895
Review

Wie antikoaguliert man ältere und fragile Patienten?

How to anticoagulate elderly and fragile patients?
Joerg Herold
  Klinikum Darmstadt, Klinik für Gefäßmedizin-Angiologie
,
Rupert Bauersachs
  Klinikum Darmstadt, Klinik für Gefäßmedizin-Angiologie
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Corrected by:

Wie antikoaguliert man ältere und fragile Patienten?Dtsch Med Wochenschr 2020; 145(21): e1-e2
DOI: 10.1055/a-1911-5468

Zusammenfassung

Mit zunehmendem Alter steigt das Risiko für Thrombosen, Blutungen und Nierenfunktionsstörungen. Die Wirksamkeit und Sicherheit der direkten oralen Antikoagulanzien (DOAKs) bei fragilen Patienten (Alter 75 Jahre und/oder Kreatinin-Clearance < 50 ml/min und/oder Körpergewicht unter 50 kg) mit Indikation zur Antikoagulation ist eines der schwierigsten Themen in der aktuellen kardiovaskulären Medizin. Neue Registerdaten aus Subgruppenanalysen großer Studien und Register weisen auf die Überlegenheit von DOAKs im Vergleich mit VKA hin. In diesem Artikel werden sowohl Daten aus neuen Studien als auch Subgruppenanalysen von wegweisenden Studien ausgewertet, um neue Erkenntnisse zu gewinnen und Wege für die Antikoagulation bei fragilen Patienten zu beschreiben.

Abstract

Risks of thrombosis, bleeding and renal impairment are increasing with age. The efficacy and safety of the direct oral anticoagulants (DOACs) in fragile patients (age > 75 years and/or creatinine clearance levels < 50 ml/min and/or body weight below 50 kg) with indication for anticoagulation is one of the most challenging topic in cardiovascular medicine. New registry data from subgroup analyses of landmark studies and registries point towards to superiority of DOACs. This article summarizes new insights and describes pathways for anticoagulation in fragile patients.

Schlüsselwörter

Antikoagulation - ältere Patienten - fragil - venöse Thromboembolien - NOAK - DOAC - VHF

Key words

anticoagulation - elderly - fragile - venous thromboembolism - NOAC - DOAC - atrial fibrillation


Publication History

Article published online:
20 October 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 López-Núñez JJ, Pérez-Andrés R, Di Micco P. et al Direct Oral Anticoagulants or Standard Anticoagulant Therapy in Fragile Patients with Venous Thromboembolism. TH Open 2019; 03: e67-e76 . doi:10.1055/s-0039-1683970
    Google Scholar
  • 2 Yamagata K, Ishida K, Sairenchi T. et al Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney international 2007; 71: 159-166 . doi:10.1038/sj.ki.5002017
    Google Scholar
  • 3 Reinecke H, Nabauer M, Gerth A. et al Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease. Kidney international 2015; 87: 200-209 . doi:10.1038/ki.2014.195
    Google Scholar
  • 4 Hart RG, Eikelboom JW, Brimble KS. et al Stroke prevention in atrial fibrillation patients with chronic kidney disease. The Canadian journal of cardiology 2013; 29: S71-S78 . doi:10.1016/j.cjca.2013.04.005
    Google Scholar
  • 5 Olesen JB, Lip GY, Kamper AL. et al Stroke and bleeding in atrial fibrillation with chronic kidney disease. The New England journal of medicine 2012; 367: 625-635 . doi:10.1056/NEJMoa1105594
    Google Scholar
  • 6 Capodanno D, Angiolillo DJ. Antithrombotic therapy in patients with chronic kidney disease. Circulation 2012; 125: 2649-2661 . doi:10.1161/CIRCULATIONAHA.111.084996
    Google Scholar
  • 7 Man-Son-Hing M, Nichol G, Lau A. et al Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Archives of internal medicine 1999; 159: 677-685
    Google Scholar
  • 8 Donze J, Clair C, Hug B. et al Risk of falls and major bleeds in patients on oral anticoagulation therapy. The American journal of medicine 2012; 125: 773-778 . doi:10.1016/j.amjmed.2012.01.033
    Google Scholar
  • 9 Heidbuchel H, Verhamme P, Alings M. et al Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2015; 17: 1467-1507 . doi:10.1093/europace/euv309
    Google Scholar
  • 10 Steffel J, Verhamme P, Potpara TS. et al The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European heart journal 2018; 39: 1330-1393 . doi:10.1093/eurheartj/ehy136
    Google Scholar
  • 11 Connolly SJ, Ezekowitz MD, Yusuf S. et al Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2009; 361: 1139-1151 . doi:10.1056/NEJMoa0905561
    Google Scholar
  • 12 Patel MR, Mahaffey KW, Garg J. et al Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England journal of medicine 2011; 365: 883-891 . doi:10.1056/NEJMoa1009638
    Google Scholar
  • 13 Granger CB, Alexander JH, McMurray JJ. et al Apixaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2011; 365: 981-992 . doi:10.1056/NEJMoa1107039
    Google Scholar
  • 14 Giugliano RP, Ruff CT, Braunwald E. et al Edoxaban versus warfarin in patients with atrial fibrillation. The New England journal of medicine 2013; 369: 2093-2104 . doi:10.1056/NEJMoa1310907
    Google Scholar
  • 15 Kimachi M, Furukawa TA, Kimachi K. et al Direct oral anticoagulants versus warfarin for preventing stroke and systemic embolic events among atrial fibrillation patients with chronic kidney disease. The Cochrane database of systematic reviews 2017; 11: CD011373 . doi:10.1002/14651858.CD011373.pub2
    Google Scholar
  • 16 Investigators E, Bauersachs R, Berkowitz SD. et al Oral rivaroxaban for symptomatic venous thromboembolism. The New England journal of medicine 2010; 363: 2499-2510 . doi:10.1056/NEJMoa1007903
    Google Scholar
  • 17 Bauersachs RM, Lensing AW, Prins MH. et al Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment. Thrombosis journal 2014; 12: 25 . doi:10.1186/1477-9560-12-25
    Google Scholar
  • 18 Lim W, Dentali F, Eikelboom JW. et al Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Annals of internal medicine 2006; 144: 673-684
    Google Scholar
  • 19 Gerlach AT, Pickworth KK, Seth SK. et al Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy 2000; 20: 771-775
    Google Scholar
  • 20 Spinler SA, Inverso SM, Cohen M. et al Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. American heart journal 2003; 146: 33-41 . doi:10.1016/S0002-8703(03)00121-2
    Google Scholar
  • 21 Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008; 4: 1065-1074 . doi:10.1517/17425255.4.8.1065
    Google Scholar
  • 22 Ansell J, Hirsh J, Hylek E. et al Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 160S-198S . doi:10.1378/chest.08-0670
    Google Scholar
  • 23 Kleinow ME, Garwood CL, Clemente JL. et al Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic. J Manag Care Pharm 2011; 17: 523-530 . doi:10.18553/jmcp.2011.17.7.523
    Google Scholar
  • 24 Prins MH, Lensing AW, Bauersachs R. et al Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thrombosis journal 2013; 11: 21 . doi:10.1186/1477-9560-11-21
    Google Scholar
  • 25 Bauersachs RM, Herold J. Oral Anticoagulation in the Elderly and Frail. Hamostaseologie 2020; 40: 74-83 . doi:10.1055/s-0040-1701476
    Google Scholar
  • 26 Soliman EZ, Prineas RJ, Go AS. et al Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). American heart journal 2010; 159: 1102-1107 . doi:10.1016/j.ahj.2010.03.027
    Google Scholar
  • 27 Eikelboom JW, Connolly SJ, Gao P. et al Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. Journal of stroke and cerebrovascular diseases: the official journal of National Stroke Association 2012; 21: 429-435 . doi:10.1016/j.jstrokecerebrovasdis.2012.05.007
    Google Scholar
  • 28 Go AS, Fang MC, Udaltsova N. et al Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Circulation 2009; 119: 1363-1369 . doi:10.1161/CIRCULATIONAHA.108.816082
    Google Scholar
  • 29 Atar I, Konas D, Acikel S. et al Frequency of atrial fibrillation and factors related to its development in dialysis patients. International journal of cardiology 2006; 106: 47-51 . doi:10.1016/j.ijcard.2004.12.048
    Google Scholar
  • 30 Marinigh R, Lip GY, Fiotti N. et al Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. Journal of the American College of Cardiology 2010; 56: 827-837 . doi:10.1016/j.jacc.2010.05.028
    Google Scholar
  • 31 Lip GY. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation. The American journal of medicine 2011; 124: 111-114 . doi:10.1016/j.amjmed.2010.05.007
    Google Scholar
  • 32 Reinecke H, Brand E, Mesters R. et al Dilemmas in the management of atrial fibrillation in chronic kidney disease. Journal of the American Society of Nephrology: JASN 2009; 20: 705-711 . doi:10.1681/ASN.2007111207
    Google Scholar
  • 33 Kirchhof P, Benussi S, Kotecha D. et al 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2016; 18: 1609-1678 . doi:10.1093/europace/euw295
    Google Scholar
  • 34 Yao X, Shah ND, Sangaralingham LR. et al Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction. Journal of the American College of Cardiology 2017; 69: 2779-2790 . doi:10.1016/j.jacc.2017.03.600
    Google Scholar
  • 35 Patti G, Pecen L, Lucerna M. et al Net Clinical Benefit of Non-Vitamin K Antagonist vs Vitamin K Antagonist Anticoagulants in Elderly Patients with Atrial Fibrillation. The American journal of medicine 2019; 132: 749-757; e745 . doi:10.1016/j.amjmed.2018.12.036
    Google Scholar
  • 36 Bohm M, Ezekowitz MD, Connolly SJ. et al Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. Journal of the American College of Cardiology 2015; 65: 2481-2493 . doi:10.1016/j.jacc.2015.03.577
    Google Scholar
  • 37 Fordyce CB, Hellkamp AS, Lokhnygina Y. et al On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF. Circulation 2016; 134: 37-47 . doi:10.1161/CIRCULATIONAHA.116.021890
    Google Scholar
  • 38 van Gorp RH, Schurgers LJ. New Insights into the Pros and Cons of the Clinical Use of Vitamin K Antagonists (VKAs) Versus Direct Oral Anticoagulants (DOACs). Nutrients 2015; 7: 9538-9557 . doi:10.3390/nu7115479
    Google Scholar
  • 39 [Anonym]. Late-Breaking Science Abstracts and Featured Science Abstracts From the American Heart Association&#x2019;s Scientific Sessions 2019 and Late-Breaking Abstracts in Resuscitation Science From the Resuscitation Science Symposium 2019. Circulation 2019; 140: e965-e1011 . doi:10.1161/CIR.0000000000000742
    Google Scholar
  • 40 Boersma LV, Schmidt B, Betts TR. et al EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology. Catheterization and cardiovascular interventions: official journal of the Society for Cardiac Angiography & Interventions 2016; 88: 460-465 . doi:10.1002/ccd.26358
    Google Scholar
  • 41 Gangireddy C, Rectenwald JR, Upchurch GR. et al Risk factors and clinical impact of postoperative symptomatic venous thromboembolism. Journal of vascular surgery 2007; 45: 335-341 ; discussion 341-332. doi:10.1016/j.jvs.2006.10.034
    Google Scholar
  • 42 Bauersachs RM. New oral anticoagulants and chronic kidney disease. Der Internist 2012; 53: 1431-1444 . doi:10.1007/s00108-012-3146-y
    Google Scholar
  • 43 Bauersachs RM. Use of anticoagulants in elderly patients. Thrombosis research 2012; 129: 107-115 . doi:10.1016/j.thromres.2011.09.013
    Google Scholar
  • 44 Monreal M, Falga C, Valle R. et al Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. The American journal of medicine 2006; 119: 1073-1079 . doi:10.1016/j.amjmed.2006.04.028
    Google Scholar
  • 45 Lip GY, Frison L, Halperin JL. et al Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. Journal of the American College of Cardiology 2011; 57: 173-180 . doi:10.1016/j.jacc.2010.09.024
    Google Scholar